Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXL770 PK and Safety Study in Healthy Subjects
NCT05441904Phase 1Completed
- Sponsor
- Poxel SA
- Start
- Mar 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PXL770 in Nonalcoholic steatohepatitis (NASH), sponsored by Poxel SA. Primary endpoints: Maximum Observed Plasma Concentration at 144 hours, Area Under the Curve at 144 hours and 5 more. Started Mar 2021; status: completed.
02
Drugs
PXL770
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05441904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441904.